Chitra Suri

TL;DR: The discovery of a negative regulator acting on Tie2 emphasizes the need for exquisite regulation of this angiogenic receptor system.

TL;DR: It is shown that mice engineered to lack Angiopoietin-1 display angiogenic deficits reminiscent of those previously seen in mice lacking TIE2, demonstrating that AngiopOietIn-1 is a primary physiologic ligand for TIE1 and that it has critical in vivo angiogenesis actions that are distinct from VEGF and that are not reflected in the classic in vitro assays used to characterize VEGf.

TL;DR: Angiopoietin-1 may be useful for reducing microvascular leakage in diseases in which the leakage results from chronic inflammation or elevated V EGF and, in combination with VEGF, for promoting growth of nonleaky vessels.

TL;DR: A vascular growth factor whose primary role is in postnatal angiogenic remodeling is defined and it is demonstrated that members of the VEGF and Angiopoietin families collaborate during development of the lymphatic vasculature.

TL;DR: It is shown that transgenic overexpression of angiopoietin-1 in the skin of mice produces larger, more numerous, and more highly branched vessels, raising the possibility that angioietins can be used, alone or in combination with VEGF to promote therapeutic angiogenesis.